Charles River (CRL) Insider Files 144 to Sell 22,500 Shares via Merrill Lynch

Rhea-AI Filing Summary

Charles River Laboratories (CRL) Form 144 discloses a proposed sale of 22,500 shares of common stock through Merrill Lynch on or about 08/18/2025 with an aggregate market value of $3,420,000. The notice identifies the seller as Richard Wallman and shows prior acquisitions by the seller including RSU vesting from 2017–2019 and multiple open-market purchases in June–July 2025 totaling 15,000 shares. The filing also reports recent sales by the same person in the past three months: 4,000 shares on 06/23/2025 for $550,000 and 8,500 shares on 07/21/2025 for $1,275,000. The filer certifies no undisclosed material adverse information.

Positive

• Planned sale fully disclosed with broker, share count (22,500) and aggregate market value ($3,420,000)
• Acquisition history provided, showing RSU vesting and recent open-market purchases which clarify holding origins and compliance with Rule 144
• Prior sales reported for transparency: 4,000 shares (06/23/2025) for $550,000 and 8,500 shares (07/21/2025) for $1,275,000

Negative

• Insider selling a significant block of 22,500 shares estimated at $3.42M, which may be perceived negatively by some investors
• Substantial prior dispositions in the past three months totaling 12,500 shares and $1.825M in gross proceeds

Insights

Securities Analyst

TL;DR: Insider Richard Wallman plans to sell 22,500 CRL shares (~$3.42M) after recent purchases and partial dispositions, a disclosure of routine insider liquidity.

The Form 144 is a routine regulatory notice showing proposed disposition of 22,500 shares via Merrill Lynch with an indicated market value of $3.42 million. The seller's holdings originate from RSU vestings (2017–2019) and recent open-market purchases in June–July 2025. The filing also documents prior sales in June and July 2025 totaling 12,500 shares and gross proceeds of $1.825 million. For investors, this is a transparency filing; it does not include operational or financial performance data.

Corporate Governance Expert

TL;DR: Disclosure complies with Rule 144; indicates insider liquidity activity but contains no governance changes or undisclosed material events.

The notice satisfies Rule 144 requirements by specifying the class, broker, number of shares, acquisition history, and recent sales. Acquisition details show a mix of RSU vesting and recent market purchases, which is relevant for assessing holding period and resale eligibility. The signer affirms absence of undisclosed material adverse information. There are no indications of orchestrated insider transfers, change in control, or governance actions in this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	22500	3420000.00	49115712	08/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/08/2017	Vesting of restricted stock unit award	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			2990	05/08/2017	Granted as part of issuer equity compensation plan
Common Stock	05/07/2018	Vesting of restricted stock unit award	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			3258	05/07/2018	Granted as part of issuer equity compensation plan
Common Stock	05/14/2019	Vesting of restricted stock unit award	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			252	05/14/2019	Granted as part of issuer equity compensation plan
Common Stock	06/23/2025	Open Market Purchase	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			4000	06/23/2025	Cash
Common Stock	06/24/2025	Open Market Purchase	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			4000	06/24/2025	Cash
Common Stock	07/01/2025	Open Market Purchase	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			2000	07/01/2025	Cash
Common Stock	07/03/2025	Open Market Purchase	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			1000	07/03/2025	Cash
Common Stock	07/21/2025	Open Market Purchase	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.			5000	07/21/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Richard Wallman 251 BALLARDVALE ST WILMINGTON MA 01887	Common Stock	06/23/2025	4000	550000.00
Richard Wallman 251 BALLARDVALE ST WILMINGTON MA 01887	Common Stock	07/21/2025	8500	1275000.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for CRL disclose?

It discloses a proposed sale of 22,500 shares of Charles River Laboratories common stock with an aggregate market value of $3,420,000, planned through Merrill Lynch around 08/18/2025.

Who is the seller named on the CRL Form 144?

The seller is identified as Richard Wallman with prior acquisitions from RSU vesting and several recent open-market purchases.

Has the seller made other sales recently?

Yes. The filing reports sales of 4,000 shares on 06/23/2025 for $550,000 and 8,500 shares on 07/21/2025 for $1,275,000.

What is the origin of the shares to be sold?

Shares were acquired via RSU vesting (2017–2019) and open-market purchases in June–July 2025, as stated in the filing.

Does the filing state any undisclosed material information?

The signer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.